vamifeport   Click here for help

GtoPdb Ligand ID: 11183

Synonyms: VIT-2763 | VIT2763
PDB Ligand
Compound class: Synthetic organic
Comment: Vamifeport (VIT-2763) is a first in-class, orally administered small molecule inhibitor of ferroportin (SLC40A1) [1]. It was developed by Vifor Pharma for the prevention of iron overload and to treat β-thalassaemia.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 10
Topological polar surface area 108.73
Molecular weight 408.17
XLogP 1.14
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=C(c1coc(n1)CCNCCc1nc2c([nH]1)cccc2)NCc1ncccc1F
Isomeric SMILES O=C(c1coc(n1)CCNCCc1nc2c([nH]1)cccc2)NCc1ncccc1F
InChI InChI=1S/C21H21FN6O2/c22-14-4-3-9-24-17(14)12-25-21(29)18-13-30-20(28-18)8-11-23-10-7-19-26-15-5-1-2-6-16(15)27-19/h1-6,9,13,23H,7-8,10-12H2,(H,25,29)(H,26,27)
InChI Key KNYVRFXIVWUGBZ-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
VIT-2763 has progressed to clinical evaluation as a novel treatment for β-thalassemia.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04364269 Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Efficacy of VIT-2763 in β-thalassaemia Phase 2 Interventional Vifor (International) Inc.